<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>prostate cancer therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/prostate-cancer-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 21 Oct 2025 14:20:35 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>prostate cancer therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Innovative Strategy Unveiled for Prostate Cancer Therapy</title>
		<link>https://bioengineer.org/innovative-strategy-unveiled-for-prostate-cancer-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 21 Oct 2025 14:20:31 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Hormone therapy resistance]]></category>
		<category><![CDATA[prostate cancer therapy]]></category>
		<category><![CDATA[Thyroid hormone receptor beta (TRβ)]]></category>
		<category><![CDATA[TRβ inhibitor NH-3]]></category>
		<category><![CDATA[Tumor growth mechanisms]]></category>
		<guid isPermaLink="false">https://bioengineer.org/innovative-strategy-unveiled-for-prostate-cancer-therapy/</guid>

					<description><![CDATA[An international collaboration spearheaded by researchers at the Medical University of Vienna has unveiled a groundbreaking connection between thyroid hormone signaling and the progression of prostate cancer. This novel discovery elucidates the pivotal role of the thyroid hormone receptor beta (TRβ) in driving tumor growth, opening new therapeutic avenues for a disease that remains the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">284415</post-id>	</item>
		<item>
		<title>Pinpointing KLK3 Targets for Prostate Cancer Therapy</title>
		<link>https://bioengineer.org/pinpointing-klk3-targets-for-prostate-cancer-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 11 Sep 2025 07:52:29 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[enzyme inhibitors]]></category>
		<category><![CDATA[in-silico drug design]]></category>
		<category><![CDATA[KLK3 targeting]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[prostate cancer therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/pinpointing-klk3-targets-for-prostate-cancer-therapy/</guid>

					<description><![CDATA[In a groundbreaking study published recently in Medical Oncology, researchers have unveiled a promising new strategy to combat prostate cancer by specifically targeting the kallikrein-related peptidase 3 (KLK3) enzyme. This innovative research combines both in-silico computational modeling and rigorous in-vitro laboratory experiments to identify potential inhibitors that can effectively disrupt KLK3’s role in prostate cancer [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">268649</post-id>	</item>
	</channel>
</rss>
